Bispebjerg Hospital

7 trials 3 recruiting Academic / non-commercial

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

4 Completed trials

1 Countries active

13 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III/IV

Phase IV

Phase III: 1 Phase II: 2 Phase III/IV: 1 Phase IV: 3

Oversight events:

2 serious breaches across 2 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Nodal osteoarthritis 1 Type 2 diabetes mellitus 1

Top IMPs

EPLERENONE 1 FUROSEMIDE 1 ISOSORBIDE DINITRATE 1 METFORMIN HYDROCHLORIDE 1 OMALIZUMAB 1 SEMAGLUTIDE 1 SPIRONOLACTONE 1

All trials

7 total

The SEMAFOOT2 Pilot. Effect of semaglutide on healing of foot ulcers in type 2 diabetes patients. A Pilot study. Recruiting

2023-504913-65-01 Phase II 1 country SEMAGLUTIDE
VASODILATATION OR LOOP-DIURETICS FOR INITIAL TREATMENT OF PULMONARY CONGESTION DUE TO ACUTE HEART FAILURE – A RANDOMIZED PLACEBO-CONTROLLED … Recruiting

2022-500035-36-01 Phase IV 1 country FUROSEMIDE; ISOSORBIDE DINITRATE
CROWD-ASPECT Recruiting

2022-502239-20-00 Phase IV 1 country EPLERENONE; SPIRONOLACTONE
Metformin treatment of patients with hand osteoarthritis: A randomised, placebo-controlled trial Ended

2023-509181-38-00 Phase III 1 country METFORMIN HYDROCHLORIDE
DANNOAC- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study Ended

2022-501912-32-00 Phase IV 1 country
Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial) Ended

2023-506187-14-00 Phase III/IV 1 country OMALIZUMAB
Treatment of Chronic Hand Eczema with Oral Roflumilast (HERO) Ended

2022-503011-42-00 Phase II 1 country

Showing 1–7 of 7 trials

← All sponsors A–Z